Compare LIQT & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIQT | MRKR |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3M | 16.6M |
| IPO Year | N/A | N/A |
| Metric | LIQT | MRKR |
|---|---|---|
| Price | $1.88 | $1.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.20 | ★ $10.17 |
| AVG Volume (30 Days) | 16.3K | ★ 330.4K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,788,295.00 | $4,694,988.00 |
| Revenue This Year | $34.09 | N/A |
| Revenue Next Year | $18.75 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.97 | N/A |
| 52 Week Low | $1.34 | $0.81 |
| 52 Week High | $3.35 | $5.95 |
| Indicator | LIQT | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 40.45 | 67.32 |
| Support Level | $1.81 | $1.40 |
| Resistance Level | $2.14 | $1.49 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 2.47 | 95.45 |
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is engaged in three businesses that are diesel particulate filters (DPF) for the control of soot from diesel engines, turnkey ceramic membranes systems, and complete water treatment plants. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, and kiln furniture. Its operating segment includes Water, Ceramics, and Plastics.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.